Dung Le, MD
Enriched profileBloomberg~Kimmel Professor of Cancer Immunotherapy; Professor of Oncology, Johns Hopkins University School of Medicine · Johns Hopkins University School of Medicine
Dung Le is Bloomberg~Kimmel Professor of Cancer Immunotherapy; Professor of Oncology, Johns Hopkins University School of Medicine at Johns Hopkins University School of Medicine. OpenAlex indexes 513 publications with 49,697 citations (h-index 67); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Dung Le as a Highly Cited Researcher (Cross-Field, 2021-2024).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Dung T. Le, MD, is Bloomberg~Kimmel Professor of Cancer Immunotherapy at Johns Hopkins University School of Medicine / Sidney Kimmel Comprehensive Cancer Center (Bloomberg~Kimmel Institute for Cancer Immunotherapy), Baltimore, MD. The public record shows 513 publications with 49,697 citations (h-index 67), centered on Pancreatic Cancer, Colorectal Cancer. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 13 companies, 3 NIH-funded awards (2012–2025).
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Pancreatic Cancer
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 27 Aug 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Shionogi IncProgram year20251 payment
- ABBVIE INC.Program year20251 payment
- Regeneron Pharmaceuticals, Inc.Program year202412 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
42.9%Phenothiazine23.2%Prochlorperazine Maleate100%Part D<11 patientsOpioid Agonist19.6%Oxycodone Hcl100%Part D<11 patientsSensory organs
35.7%Corticosteroid35.7%Dexamethasone100%Part D<11 patientsMetabolism & gastrointestinal
21.4%Serotonin-3 Receptor Antagonist21.4%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2012–2025 per NIH RePORTER. The latest:
- A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
Johns Hopkins University
FY2025$669,436P01CA247886 - A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
Johns Hopkins University
FY2024$635,965P01CA247886 - A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
Johns Hopkins University
FY2023$656,048P01CA247886
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.
Nature communications
Article2026 - Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses.
Cancer immunology research
Article2026 - A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.
Cancer immunology research
Clinical Trial2026 - Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Clinical cancer research
Clinical Trial2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/dung-le-md-cecc81b8
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/hopkinskimmel_congratulations-to-dr-dung-le-on-being-appointed-activity-6987781180964143104-broR
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
Johns Hopkins Kimmel Cancer Center LinkedIn post congratulating Dr. Dung Le on her appointment (Bloomberg~Kimmel Professorship)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.hopkinsmedicine.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.hopkinsmedicine.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- National Principal Investigator
multi-center clinical trials of anti-PD-1 therapy in mismatch-repair-deficient tumors, and CRS-207/GVAX listeria-vaccine platform trials in pancreatic cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pathology.jhu.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Cross-Field2021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- Bloomberg~Kimmel Professorship in Cancer Immunotherapy (named professorship, est. 2018)
appointed to Dr. Le
2018provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Pancreatic Cancer Action Network (PanCAN) Fredman Family Foundation - Research Acceleration Network Grant
$1 million, 2014 (Principal Investigator)
2014verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pancan.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Secondary affiliations
appointments beyond the home institution- Member
Johns Hopkins Kimmel Cancer Center; Skip Viragh Center for Pancreatic Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pure.johnshopkins.edu ↗
Media & interviews
press, podcasts and appearances- "Leading Oncologist Answers Questions on Keytruda Drug for Pancreatic Cancer"
featured interview, Pancreatic Cancer Action Network (PanCAN) stories
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pancan.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pathology.jhu.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine